BioSpace News Archive

Duplex Sequencing is a commonly used technique to improve DNA sequencing accuracy. Duplex Sequencing was developed to detect rare nucleotide polymorphism.

A cell bank refers to a facility that helps in the storage of cells of certain genome for future use in medicinal needs or in some product.

Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the nomination of Agnete Fredriksen, Ph.D., to the Company’s Board of Directors proposed for election at the 2021 Annual General Meeting on April 21, 2021.

American CryoStem Corporation a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced that it has begun processing patient’s adipose tissue and culturing mesenchymal stem cells, for use in its FDA approved IND Phase I Clinical Trial.

BI-1607 designed to boost efficacy and overcome patients’ resistance to clinically validated antibody therapy

ITM AG announced that the company will present a poster describing the clinical trial design for its ongoing phase III trial COMPETE for their lead candidate, no-carrier-added Lutetium-177-Edotreotide, a Targeted Radionuclide Therapy for gastroenteropancreatic neuroendocrine tumors, at the upcoming American Association of Cancer Research Virtual Annual Meeting on April 10-15, 2021 and May 17-21, 2021.

Centessa Pharmaceuticals (“Centessa”), a pharmaceutical company consisting of 10 subsidiary companies advancing a portfolio of high conviction programs with strong biological validation, today announced key additions to its leadership team. Gregory Weinhoff, M.D., MBA, joined the team as chief financial officer, while Mary Lynne Hedley, Ph.D., Robert M. Califf, M.D., MACC, and Samarth Kulkarni, Ph.D.,

- Preliminary safety, efficacy and translational data from gavo-cel Phase 1 trial at AACR 2021 - Preclinical data on autologous CD70 and allogeneic mesothelin TRuC data at AACR 2021 - Raised gross proceeds of $140M in a follow-on offering in January; extended cash runway into 2024

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced an upcoming virtual poster presentation at the 2021 American Association for Cancer Research Annual Meeting, taking place April 10-15 and May 17-21, 2021.

MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that it has raised more than $3 million in an oversubscribed bridge financing led by its existing and new investors.